World's Best Scientists 2026 revealed!
Award Badge
Immunology
USA
2026

D-Index & Metrics

Immunology

D-Index
145
Citations
93657
World Ranking
138
National Ranking
91

Medicine

D-Index
145
Citations
93650
World Ranking
1371
National Ranking
797

Douglas T. Golenbock publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Douglas T. Golenbock sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 354 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Douglas T. Golenbock D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Douglas T. Golenbock sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 145 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Immunology in United States Leader Award
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Douglas T. Golenbock is affiliated with the University of Massachusetts Chan Medical School in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a significant focus on several specialized subfields, including Immunology, Molecular Biology, Public Health, Environmental and Occupational Health, Infectious Diseases, and Parasitology.

The scientist's research covers multiple topics, notably:

  • Malaria Research and Control
  • Immune Response and Inflammation
  • Interferon and immune responses
  • Inflammasome and immune disorders
  • Mosquito-borne diseases and control
  • RNA and protein synthesis mechanisms
  • HIV Research and Treatment

Douglas T. Golenbock has contributed to numerous peer-reviewed publications. Some of their recent papers include:

  • "Immediate and long-term consequences of COVID-19 infections for the development of neurological disease," 2020, published in Alzheimer's Research & Therapy
  • "Human endogenous retrovirus HERV-K(HML-2) RNA causes neurodegeneration through Toll-like receptors," 2020, published in JCI Insight
  • "The IRAK4 scaffold integrates TLR4-driven TRIF and MYD88 signaling pathways," 2022, published in Cell Reports
  • "Itaconate impairs immune control of Plasmodium by enhancing mtDNA-mediated PD-L1 expression in monocyte-derived dendritic cells," 2024, published in Cell Metabolism
  • "Asymptomatic Plasmodium vivax malaria in the Brazilian Amazon: Submicroscopic parasitemic blood infects Nyssorhynchus darlingi," 2021, published in PLoS neglected tropical diseases

The main publication venues for their research include:

  • PLoS neglected tropical diseases
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cell Reports
  • Nature Communications
  • Nature Immunology

Douglas T. Golenbock frequently collaborates with several coauthors within their field. These include Ricardo T. Gazzinelli, Katherine A. Fitzgerald, Danielle Fernandes Durso, Evelyn A. Kurt-Jones, and Michael T. Heneka.

Among their professional recognitions, Douglas T. Golenbock has been named a Member of the Association of American Physicians.

Best Publications

  • Neuroinflammation in Alzheimer's disease

    Michael T Heneka;Monica J Carson;Joseph El Khoury;Gary E Landreth

  • IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.

    Katherine A. Fitzgerald;Sarah M. McWhirter;Kerrie L. Faia;Daniel C. Rowe

  • NLRP3 is activated in Alzheimer´s disease and contributes to pathology in APP/PS1 mice

    Michael T. Heneka;Markus P. Kummer;Andrea Stutz;Andrea Delekate

  • The NALP3 inflammasome is involved in the innate immune response to amyloid-beta.

    Annett Halle;Veit Hornung;Gabor C Petzold;Cameron R Stewart

  • Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction *

    Jesse C. Chow;Donna W. Young;Douglas T. Golenbock;William J. Christ

  • Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus.

    Evelyn A. Kurt-Jones;Lana Popova;Laura Kwinn;Lia M. Haynes

  • The History of Toll-like Receptors - Redefining Innate Immunity

    Luke A. J. O'Neill;Douglas Golenbock;Andrew G. Bowie

  • CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer

    Cameron R Stewart;Lynda M Stuart;Kim Wilkinson;Janine M van Gils

  • TLR9 signals after translocating from the ER to CpG DNA in the lysosome

    Eicke Latz;Annett Schoenemeyer;Alberto Visintin;Katherine A. Fitzgerald

  • Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.

    Jane Tian;Ana Maria Avalos;Su-Yau Mao;Bo Chen

  • LPS-TLR4 Signaling to IRF-3/7 and NF-κB Involves the Toll Adapters TRAM and TRIF

    Katherine A. Fitzgerald;Daniel C. Rowe;Betsy J. Barnes;Daniel R. Caffrey

  • Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2

    Atsutoshi Yoshimura;Egil Lien;Robin R. Ingalls;Elaine Tuomanen

  • NLRP3 inflammasome activation drives tau pathology

    Christina Ising;Carmen Venegas;Shuangshuang Zhang;Hannah Scheiblich

  • TOLL-LIKE RECEPTOR 2 FUNCTIONS AS A PATTERN RECOGNITION RECEPTOR FOR DIVERSE BACTERIAL PRODUCTS

    Egil Lien;Egil Lien;Timothy J. Sellati;Atsutoshi Yoshimura;Trude H. Flo

  • Human Toll-Like Receptors Mediate Cellular Activation by Mycobacterium tuberculosis

    Terry K. Means;Shuyan Wang;Egil Lien;Atsutoshi Yoshimura

  • Identification of a key pathway required for the sterile inflammatory response triggered by dying cells

    Chun-Jen Chen;Hajime Kono;Douglas Golenbock;George Reed

  • Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9

    Terry K. Means;Eicke Latz;Fumitaka Hayashi;Mandakolathur R. Murali

  • HMGB1 signals through toll-like receptor (TLR) 4 and TLR2.

    Man Yu;Haichao Wang;Aihao Ding;Douglas T Golenbock

  • Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease

    Carmen Venegas;Sathish Kumar;Bernardo S. Franklin;Tobias Dierkes

  • CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation

    Frederick J Sheedy;Alena Grebe;Katey J Rayner;Parisa Kalantari

  • Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide

    Egil Lien;Terry K. Means;Holger Heine;Atsutoshi Yoshimura

Frequent Co-Authors

Eicke Latz
Eicke Latz German Rheumatism Research Centre
Ricardo T. Gazzinelli
Ricardo T. Gazzinelli Universidade Federal de Minas Gerais
Katherine A. Fitzgerald
Katherine A. Fitzgerald University of Massachusetts Chan Medical School
Egil Lien
Egil Lien University of Massachusetts Chan Medical School
Terje Espevik
Terje Espevik Norwegian University of Science and Technology
Evelyn A. Kurt-Jones
Evelyn A. Kurt-Jones University of Massachusetts Chan Medical School
Michael T. Heneka
Michael T. Heneka University Hospital Bonn
Shizuo Akira
Shizuo Akira Osaka University
Matthew J. Fenton
Matthew J. Fenton National Institute of Allergy and Infectious Diseases
Robert W. Finberg
Robert W. Finberg University of Massachusetts Chan Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology opens numerous doors in healthcare, including advanced nursing roles that require specialized knowledge of the immune system. For those interested in mental health, pursuing one of the best online psychiatric mental health nurse practitioner programs can provide excellent clinical placement opportunities. These programs prepare nurses to address complex psychiatric conditions with immunological implications.

Cost is often a concern when selecting a program. It’s helpful to explore options like the cheap psych np programs that still offer quality education. Affordability combined with strong curriculum can lead to robust career paths without undue financial burden.

Graduates with a Doctor of Nursing Practice (DNP) degree often see rewarding salaries, but compensation varies widely. Understanding how much do dnp nurses make in different states can influence career decisions and geographic preferences.

Additionally, for nurses looking to specialize further, learning fnp to acnp transition strategies is crucial. This shift enables practitioners to treat acute and critical care patients, often incorporating immunological expertise critical in such settings.

Best Scientists Citing Douglas T. Golenbock

Trending Scientists

Recently Published Articles